Aberer, F.; Pieber, T.R.; Eckstein, M.L.; Sourij, H.; Moser, O.
Glucose-Lowering Therapy beyond Insulin in Type 1 Diabetes: A Narrative Review on Existing Evidence from Randomized Controlled Trials and Clinical Perspective. Pharmaceutics 2022, 14, 1180.
https://doi.org/10.3390/pharmaceutics14061180
AMA Style
Aberer F, Pieber TR, Eckstein ML, Sourij H, Moser O.
Glucose-Lowering Therapy beyond Insulin in Type 1 Diabetes: A Narrative Review on Existing Evidence from Randomized Controlled Trials and Clinical Perspective. Pharmaceutics. 2022; 14(6):1180.
https://doi.org/10.3390/pharmaceutics14061180
Chicago/Turabian Style
Aberer, Felix, Thomas R. Pieber, Max L. Eckstein, Harald Sourij, and Othmar Moser.
2022. "Glucose-Lowering Therapy beyond Insulin in Type 1 Diabetes: A Narrative Review on Existing Evidence from Randomized Controlled Trials and Clinical Perspective" Pharmaceutics 14, no. 6: 1180.
https://doi.org/10.3390/pharmaceutics14061180
APA Style
Aberer, F., Pieber, T. R., Eckstein, M. L., Sourij, H., & Moser, O.
(2022). Glucose-Lowering Therapy beyond Insulin in Type 1 Diabetes: A Narrative Review on Existing Evidence from Randomized Controlled Trials and Clinical Perspective. Pharmaceutics, 14(6), 1180.
https://doi.org/10.3390/pharmaceutics14061180